CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 30 target
Drug / intervention
JS201 combine with Lenvatinibdrug
Likely dose
JS201 combine with Lenvatinib 300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04951947
NCT04951947Phase 2RecruitingUpdate OverdueUpdated 21mo ago · Completion was 18mo ago
Enrollment Stalled
Long Recruiting
Update Overdue
CompareCT.gov

A Prospective, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer With Previous Chemotherapy Combined With PD-L1 Failure

Hunan Province Tumor Hospital·interventional·Posted Jul 7, 2021·Updated Sep 19, 2024

In Brief

A Phase 2 clinical trial evaluating JS201 combine with Lenvatinib for Small-cell Lung Cancer. Currently recruiting, targeting 30 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

This is a prospective, single-arm phase II clinical study to evaluate the efficacy and safety of JS-201 combined with lenvatinib in the treatment of small-cell lung cancer that has failed previous chemotherapy combined with PD-L1. The primary observational endpoint is ORR, and the secondary observational endpoint is PFS, OS. The intervention mode is JS201 300mg i.v Q2w, lenvatinib 8mg po. Qd.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmall-cell Lung Cancer
CountriesChina
Collaborators--

Timeline

Phase 2RecruitingOverdue
20222023202420252026
First PostedJul 7, 2021
Enrollment StartJun 1, 2023
Primary CompletionDec 1, 2024
Study CompletionJun 1, 2025
TodayJul 1, 2026
Enrollment to primary: 1.5 yearsPosted 5.0 years ago

Interventions

JS201 combine with Lenvatinibdrug

JS201 300mg i.v Q2wLenvatinib 8mg po. Qd